Non-Motor Symptoms in Patients with Parkinson’s Disease – Correlations with Inflammatory Cytokines in Serum
Open accessThe DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Parkinson's Disease (PD) is the second most common neurodegenerative disorder of the central nervous system. Motor symptoms are the focus of pharmacotherapy, yet non-motor features of the disease (e.g. fatigue, mood disturbances, sleep disturbances and symptoms of anxiety) are both common and disabling for the patient. The pathophysiological mechanisms behind the non-motor symptoms in PD are yet to be untangled. The main objective of this study was to investigate associations between pro-inflammatory substances and non-motor symptoms in patients with PD. METHODS AND MATERIALS: We measured C-reactive protein, interleukin (IL)-6, soluble IL-2 receptor (sIL-2R) and tumor necrosis factor-α (TNF-α) in blood samples from PD patients (n=86) and healthy controls (n=40). Symptoms of fatigue, depression, anxiety and sleeping difficulties were assessed using the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT), the Hospital Anxiety and Depression Scale (HAD), and the Scales for Outcome in PD-Sleep Scale respectively. RESULTS: IL-6 was significantly higher in PD patients than in healthy controls. Compared to healthy controls, PD patients displayed significantly higher mean scores on HAD and lower scores on FACIT, thus indicating more severe symptoms as measured with these scales. Within the PD sample, high levels of both sIL-2R and TNF-α were significantly associated with more severe symptoms assessed by means of FACIT and HAD (depression and anxiety subscales). SIL-2-R levels were able to significantly predict FACIT and HAD scores after the effects of age, gender, anti-parkinsonian medications, and severity of motor symptoms were controlled for. DISCUSSION: We suggest that non-motor symptoms in PD patients, such as fatigue and depressive symptoms, might be generated via inflammatory mechanisms. This knowledge might contribute to the development of novel treatment options in PD, specifically targeting non-motor symptoms.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Increased levels of IL-6 in PD patients’ serum have been reported in a number of studies [254,255,256]”
From Ageing, Cellular Senescence and Neurodegenerative Disease (2018) · cites this paper as [254]
In the citing paper
“proinflammatory cytokines could play a role in the nonmotor symptoms of PD [42]”
From Neuroprotective Effect of Ceftriaxone on MPTP‐Induced Parkinson’s Disease Mouse Model by Regulating Inflammation and Intestinal Microbiota (2021) · cites this paper as [42]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Hospital Anxiety and Depression Scale
Zigmond, A. S., & Snaith, R. P. (1983) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1983.tb09716.x · Cited by 47,139
Systematic review of levodopa dose equivalency reporting in Parkinson's disease
Tomlinson, C. L., Stowe, R., Patel, S., Rick, C., Gray, R., & Clarke, C. E. (2010) · Movement Disorders · doi:10.1002/mds.23429 · Cited by 4,219
Epidemiology of Parkinson's disease
de Lau, L. M., & Breteler, M. M. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70471-9 · Cited by 4,110
Diagnostic Criteria for Parkinson Disease
Gelb, D. J., Oliver, E., & Gilman, S. (1999) · Archives of Neurology · doi:10.1001/archneur.56.1.33 · Cited by 2,822
Interleukin-2: Inception, Impact, and Implications
Smith, K. A. (1988) · Science · doi:10.1126/science.3131876 · Cited by 2,153
Twenty years of research on cytokine-induced sickness behavior
Dantzer, R., & Kelley, K. W. (2007) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2006.09.006 · Cited by 1,420
Cytokines and major depression
Schiepers, O. J. G., Wichers, M. C., & Maes, M. (2005) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2004.11.003 · Cited by 1,235 · cited 5×
“However, there are preliminary clinical trials of MDD patients without PD indicating that NSAIDs as add-on to conventional antidepressants may have beneficial effects on depressive symptoms [42,43].”
InfluentialLiu, Y., Ho, R. C.-M., & Mak, A. (2012) · Journal of Affective Disorders · doi:10.1016/j.jad.2011.08.003 · Cited by 948
Hospital Anxiety and Depression Scale
Zigmond, A. S., & Snaith, R. P. (2013) · PsycTESTS Dataset · doi:10.1037/t03589-000 · Cited by 946
Blum-Degena, D., Müller, T., Kuhn, W., Gerlach, M., Przuntek, H., & Riederer, P. (1995) · Neuroscience Letters · doi:10.1016/0304-3940(95)12192-7 · Cited by 801
Cited by
Items 101–200 of 250
Söderbom, G., & Zeng, B. (2020) · International review of neurobiology · doi:10.1016/bs.irn.2020.03.023 · Cited by 35
Austin, K. W., Ameringer, S., & Cloud, L. J. (2016) · Parkinson s Disease · doi:10.1155/2016/9869712 · Cited by 35
Moghaddam, H. S., Valitabar, Z., Ashraf-ganjouei, A., Zadeh, M. M., Sherbaf, F. G., & Aarabi, M. (2018) · Neuromolecular medicine · doi:10.1007/s12017-018-8499-5 · Cited by 31
Biomarkers for Dementia, Fatigue, and Depression in Parkinson's Disease
Prell, T., Witte, O. W., & Großkreutz, J. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.00195 · Cited by 33
Sawada, H., Oeda, T., Umemura, A., Tomita, S., Hayashi, R., Kohsaka, M., Yamamoto, K., Sudoh, S., & Sugiyama, H. (2014) · PLoS ONE · doi:10.1371/journal.pone.0085886 · Cited by 33
Peripheral Biomarkers of Parkinson’s Disease Progression and Pioglitazone Effects
Simon, D. K., On behalf of the NINDS NET-PD Investigators, Simuni, T., Elm, J. J., Clark, J., Graebner, A. K., Baker, L., Dunlop, S. R., Emborg, M. E., Kamp, C., et al. (2015) · Journal of Parkinson s Disease · doi:10.3233/jpd-150666 · Cited by 32
Redenšek, S., Flisar, D., Kojović, M., Kramberger, M. G., Georgiev, D., Pirtošek, Z., Trošt, M., & Dolžan, V. (2019) · Journal of Neuroinflammation · doi:10.1186/s12974-019-1439-y · Cited by 32
Smith, K. C., Suescun, J., Li, K., Luo, S., Bick, D. L. M., & Schiess, M. C. (2016) · NeuroImmunoModulation · doi:10.1159/000460297 · Cited by 32
Tylutka, A., Zabinski, P., Walas, Ł., & Zembroń-Lacny, A. (2024) · Aging and Disease · doi:10.14336/ad.2024.1174 · Cited by 24
A Focus on Astrocyte Contribution to Parkinson’s Disease Etiology
Prunell, G., & Olivera‐Bravo, S. (2022) · Biomolecules · doi:10.3390/biom12121745 · Cited by 29
Tobacco Use, Oral Health, and Risk of Parkinson's Disease
Liu, Z., Roosaar, A., Axéll, T., & Ye, W. (2016) · American Journal of Epidemiology · doi:10.1093/aje/kww146 · Cited by 29
Salsolinol—neurotoxic or Neuroprotective?
Kurnik‐Łucka, M., Latacz, G., Martyniak, A., Bugajski, A. J., Kieć‐Kononowicz, K., & Gil, K. (2019) · Neurotoxicity Research · doi:10.1007/s12640-019-00118-7 · Cited by 28
Aktaş, B. (2023) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-023-01319-7 · Cited by 28
Paraquat and psychological stressor interactions as pertains to Parkinsonian co-morbidity
Rudyk, C., Litteljohn, D., Syed, S., Dwyer, Z., & Hayley, S. P. (2015) · Neurobiology of Stress · doi:10.1016/j.ynstr.2015.09.001 · Cited by 28
Inflammatory markers and depression in Parkinson’s disease: a systematic review
Ramanzini, L. G., Camargo, L. F. M., Silveira, J. O. F., & Bochi, G. V. (2022) · Neurological Sciences · doi:10.1007/s10072-022-06363-7 · Cited by 27
Trimethylamine N-oxide: role in cell senescence and age-related diseases
Zhang, L., Yu, F., & Xia, J. (2022) · European Journal of Nutrition · doi:10.1007/s00394-022-03011-w · Cited by 21
Effects of the COVID-19 Pandemic on Parkinson’s Disease: a Single-Centered Qualitative Study
Anghelescu, B. A.-M., Bruno, V. A., Martino, D., & Roach, P. (2021) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/cjn.2021.70 · Cited by 26
Kobo, H., Bar‐Shira, A., Dahary, D., Gan‐Or, Z., Mirelman, A., Goldstein, O., Giladi, N., & Orr‐Urtreger, A. (2015) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2015.09.005 · Cited by 26
Guo, Y., Zhuang, X., Xian, W., Wu, L., Huang, Z., Hu, X., Zhang, X., Chen, L., & Liao, X. (2017) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12711 · Cited by 26
Blood Biomarkers in Patients with Parkinson’s Disease: A Review in Context of Anesthetic Care
Joo, J. D., Jeong, J., & Park, H. J. (2023) · Diagnostics · doi:10.3390/diagnostics13040693 · Cited by 25
Peripheral Humoral Immune Response Is Associated With the Non-motor Symptoms of Parkinson’s Disease
Sun, C., Yu, W., Zhao, Z., Song, C., Liu, Y., Jia, G., Wang, X., & Liu, Y. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.01057 · Cited by 25
TNFα increases tyrosine hydroxylase expression in human monocytes
Gopinath, A., Badov, M., Francis, M. L., Shaw, G., Collins, A., Miller, D. R., Hansen, C. A., Mackie, P. M., Tansey, M. G., Dagra, A., et al. (2021) · npj Parkinson s Disease · doi:10.1038/s41531-021-00201-x · Cited by 25
Ramadan, M. E., Mostafa, T. M., Ghali, A. A., & El‐Afify, D. (2025) · Inflammopharmacology · doi:10.1007/s10787-025-01752-8 · Cited by 23
Dietary Patterns and Nonmotor Symptoms in Parkinson’s Disease: A Cross-Sectional Analysis
Lawrie, S., Coe, S., Mansoubi, M., Welch, J., Razzaque, J., Hu, M. T., & Dawes, H. (2022) · Journal of the American Nutrition Association · doi:10.1080/07315724.2022.2056544 · Cited by 23
Wang, L., Yi, H., Liang, X., Xu, F., Li, T., Yang, X., Wei, M., Ou, Z., & Tong, Q. (2023) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2023.578222 · Cited by 22
Alpha Synuclein Toxicity and Non-Motor Parkinson’s
Mazzotta, G. M., & Conte, C. (2024) · Cells · doi:10.3390/cells13151265 · Cited by 22
Molecular basis of the development of Parkinson’s disease
Absalyamova, M. T., Traktirov, D. S., Burdinskaya, V. O., Artemova, V., Muruzheva, Z. M., & Karpenko, M. N. (2024) · Neuroscience · doi:10.1016/j.neuroscience.2024.12.009 · Cited by 22
Effects of fatigue on cognitive control in neurosarcoidosis
Beste, C., Kneiphof, J., & Woitalla, D. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.01.012 · Cited by 22
Psychosis in Parkinson's disease: From the soft signs to the hard science
Lenka, A., Herath, P., Christopher, R., & Pal, P. K. (2017) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2017.06.011 · Cited by 22
Treatment With the CSF1R Antagonist GW2580, Sensitizes Microglia to Reactive Oxygen Species
Soto‐Díaz, K., Vailati-Riboni, M., Louie, A. Y., McKim, D. B., Gaskins, H. R., Johnson, R. W., & Steelman, A. J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.734349 · Cited by 22
Circulating levels of adipokines in Parkinson's disease
Rocha, N. P., Scalzo, P. L., Barbosa, I. G., de Sousa, M. S., Morato, I. B., Vieira, É. L. M., Christo, P. P., Reis, H. J., & Teixeira, A. L. (2014) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2014.01.021 · Cited by 22
Zhang, T., Luu, M. D. A., Dolga, A. M., Eisel, U. L. M., & Schmidt, M. (2023) · Frontiers in Physiology · doi:10.3389/fphys.2023.1207280 · Cited by 21
Depression Is Associated With Constipation in Patients With Parkinson's Disease
Qin, X., Gang, C., Bo, L., Li, Z., Liu, X., Li, X., Shi, M., Yin-zhen, D., Chen, X., & Dian-shuai, G. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.567574 · Cited by 21
Serum Inflammatory Profile for the Discrimination of Clinical Subtypes in Parkinson's Disease
Yılmaz, R., Strafella, A., Bernard, A., Schulte, C., van den Heuvel, L., Schneiderhan-Marra, N., Knorpp, T., Joos, T., Leypoldt, F., Geritz, J., et al. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2018.01123 · Cited by 18
Palmas, M. F., Ena, A., Burgaletto, C., Casu, M., Cantarella, G., Carboni, E., Etzi, M., Simone, A. D., Fusco, G., Cardia, M., et al. (2022) · Neurotherapeutics · doi:10.1007/s13311-022-01182-2 · Cited by 14
Chmiel, J., Rybakowski, F., & Leszek, J. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13030699 · Cited by 20
Swann, P., Mirza-Davies, A., & O'Brien, J. T. (2024) · Journal of Inflammation Research · doi:10.2147/jir.s385825 · Cited by 19
Metabolomic analysis of serum using proton NMR in 6-OHDA experimental PD model and patients with PD
Kumari, S., Kumaran, S. S., Goyal, V., Bose, S., Jain, S., Dwivedi, S. N., Srivastava, A. K., & Jagannathan, N. R. (2020) · Neurochemistry International · doi:10.1016/j.neuint.2020.104670 · Cited by 19
Zaehle, T. (2021) · Brain Sciences · doi:10.3390/brainsci11040467 · Cited by 19
Emerging urinary alpha-synuclein and miRNA biomarkers in Parkinson’s disease
Giri, B., Seamon, M., Banerjee, A., Chauhan, S., Purohit, S. B., Morgan, J. C., Baban, B., & Wakade, C. G. (2021) · Metabolic Brain Disease · doi:10.1007/s11011-021-00735-2 · Cited by 19
Elkattan, M., Rashed, L. A., Shazly, S. R., & Ismail, R. S. (2022) · The Egyptian Journal of Neurology Psychiatry and Neurosurgery · doi:10.1186/s41983-022-00460-2 · Cited by 19
Bo, L., Guojun, T., & Guo, L. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01363 · Cited by 19
Molecular biomarkers of glial activation and injury in epilepsy
Kalsariya, R. A., Kavila, D., Shorter, S. A., Negi, D., Goodall, I. C. A., Boussios, S., & Ovsepian, S. V. (2025) · Drug Discovery Today · doi:10.1016/j.drudis.2025.104289 · Cited by 17
TLR4 and TLR2 activation is differentially associated with age during Parkinson’s disease
Sobrinho, H. M. D. R., da Silva, D. J., Gomides, L. F., Dorta, M. L., de Oliveira, M. A. P., & Ribeiro‐Dias, F. (2017) · Immunological Investigations · doi:10.1080/08820139.2017.1379024 · Cited by 17
Il-10 signaling reduces survival in mouse models of synucleinopathy
Cockey, S. G., McFarland, K. N., Koller, E. J., Brooks, M., Cruz, E. G. D. L., Cruz, P. E., Ceballos‐Diaz, C., Rosario, A. M., Levites, Y., Borchelt, D., et al. (2021) · npj Parkinson s Disease · doi:10.1038/s41531-021-00169-8 · Cited by 17
Niacin for Parkinson's disease
Seamon, M., Purohit, S. B., Giri, B., Baban, B., Morgan, J. C., Chong, R. K. Y., & Wakade, C. G. (2019) · Clinical and Experimental Neuroimmunology · doi:10.1111/cen3.12553 · Cited by 16
Jiao, F., Zhou, L., & Wu, Z. (2024) · Neurological Sciences · doi:10.1007/s10072-024-07878-x · Cited by 15
Hu, Y., Guo, P. F., Lian, T., Zuo, L.-J., Yu, S., Liu, L., Jin, Z. Y., Yu, Q.-J., Wang, R., Li, L., et al. (2021) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s272110 · Cited by 15
Zhang, Y., & Xu, X. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.879459 · Cited by 15
Fatigue in Parkinson’s Disease Associates with Lower Ambulatory Diastolic Blood Pressure
Kotagal, V., Szpara, A., Albin, R. L., & Bohnen, N. I. (2019) · Journal of Parkinson s Disease · doi:10.3233/jpd-191579 · Cited by 15
Hu, S., Huang, S., Ma, J., Li, D., Zhao, Z., Zheng, J., Li, M., Wang, Z., Sun, W., & Shi, X. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.689939 · Cited by 15
Perception of Swallowing-Related Fatigue Among Older Adults
Brates, D., Harel, D., & Molfenter, S. M. (2022) · Journal of Speech Language and Hearing Research · doi:10.1044/2022_jslhr-22-00151 · Cited by 14
Okruszko, M. A., Szabłowski, M., Zarzecki, M., Michnowska‐Kobylińska, M., Lisowski, Ł., Łapińska, M., Stachurska, Z., Szpakowicz, A., Kamiński, K. A., & Konopińska, J. (2024) · Journal of Inflammation Research · doi:10.2147/jir.s434989 · Cited by 14
Alagoz, A., Dağdaş, A., Bünül, S. D., & Erci, G. C. (2025) · Biomedicines · doi:10.3390/biomedicines13082029 · Cited by 13
Serum adiponectin levels between patients with Parkinson’s disease and those with PSP
Kataoka, H., & Sugie, K. (2020) · Neurological Sciences · doi:10.1007/s10072-019-04216-4 · Cited by 13
Sobrinho, H. M. D. R., Gomes, R. S., da Silva, D. J., Quixabeira, V. B. L., Joosten, L. A. B., Cardoso, C. R. D. B., & Ribeiro‐Dias, F. (2021) · Journal of Neuroscience Research · doi:10.1002/jnr.24916 · Cited by 13
Chang, Y., Lee, M., Wu, D., Tsai, J., Ho, P., Lin, C. R., & Chuang, H. (2020) · PLoS ONE · doi:10.1371/journal.pone.0236443 · Cited by 14
Moon, S., Sarmento, C. V. M., Smirnova, I. V., Colgrove, Y., Lai, S., Lyons, K. E., & Liu, W. (2024) · Journal of Bodywork and Movement Therapies · doi:10.1016/j.jbmt.2024.07.025 · Cited by 12
Associations of inflammatory cytokines and cortisol with nonmotor features of Huntington's disease
Bilal, H., McDonald, S. J., Stout, J. C., & Harding, I. H. (2024) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.52016 · Cited by 12
Zheng, H., Qian, X., Tian, W., & Cao, L. H. (2022) · Brain Sciences · doi:10.3390/brainsci12060774 · Cited by 12
Unda, S. R., Antoniazzi, A. M., Altschul, D., & Marongiu, R. (2021) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000516340 · Cited by 11
Fang, X. (2018) · Metabolic Brain Disease · doi:10.1007/s11011-018-0239-x · Cited by 11
Fan, Y., Li, X., Ma, J., Yang, D., Liang, K., Shen, Y. M., Wei, W., Dong, L., Liu, C., She, Z., et al. (2024) · Journal of Neuroscience Research · doi:10.1002/jnr.25303 · Cited by 10
Richardson, K., Huber, J. E., Kiefer, B., & Snyder, S. (2022) · American Journal of Speech-Language Pathology · doi:10.1044/2022_ajslp-22-00026 · Cited by 9
Mikrobiyota ve Nörodejenerasyon
Alagöz, A. N. (2017) · JOURNAL OF BIOTECHNOLOGY AND STRATEGIC HEALTH RESEARCH · Cited by 9
Clinically proven natural products in aid of treating Parkinson's disease: a comprehensive review
Roni, M. A. H., Jami, M. A. B. S., Hoque, S., Hasibuzzaman, M. A., Banu, K. H., Rozina, Ansari, F., Sohel, M., Ashifuzzaman, M., Joy, F.-U.-H., et al. (2024) · Current Medicine · doi:10.1007/s44194-024-00033-w · Cited by 8
Li, Y., Jia, W., Chen, C., Chen, C., Chen, J., Yang, X., & Liu, P. (2025) · PLoS ONE · doi:10.1371/journal.pone.0320257 · Cited by 8
Hagan, A. J., & Kumar, R. (2023) · Clinical Neuropharmacology · doi:10.1097/wnf.0000000000000572 · Cited by 8
Ning, H., Zhou, H., Yang, N., Ren, J., Wang, H., Liu, W., & Zhao, Y. (2023) · Experimental Gerontology · doi:10.1016/j.exger.2023.112295 · Cited by 7
Gupta, S. D., Ahuja, N., Kumar, S., Arora, R., Kumawat, S., Kaushal, V., & Gupta, P. K. (2024) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2024.07.025 · Cited by 7
Murtala, A. A., Oyinloye, O. E., Oladoja, F. A., Adetutu, K. O., Olashore, A. H. S., Ogunjimi, L., Aderionla, A. A., Olooto, W. E., Soyinka, O. O., Fageyinbo, M. S., et al. (2024) · Pharmacological Research - Modern Chinese Medicine · doi:10.1016/j.prmcm.2024.100375 · Cited by 7
Fatigue and neuropsychiatric symptoms in Parkinson’s disease: a narrative review
Bojtos, L., Rodríguez-Antigüedad, J., Pagonabarraga, J., Martínez‐Horta, S., & Kulisevsky, J. (2025) · Frontiers in Neurology · doi:10.3389/fneur.2025.1670644 · Cited by 7
Biomarkers of sleep disturbance in adults with chronic illness: A scoping review
Winders, S., Lyon, D., Stechmiller, J. K., & Kelly, D. L. (2022) · Chronic Illness · doi:10.1177/17423953211073697 · Cited by 6
Vega-Angeles, V. T., Morales-Ruiz, V., & Adalid-Peralta, L. V. (2024) · Revista de investigaci�n Cl�nica · doi:10.24875/ric.24000068 · Cited by 6
Matias, K. V., Gonçalves, V., Scorza, F. A., Finsterer, J., Ciconelli, R. M., & Scorza, C. A. (2025) · Molecules · doi:10.3390/molecules30081672 · Cited by 6
Fardell, C., Schiöler, L., Nissbrandt, H., Torén, K., & Åberg, M. (2020) · Journal of Neurology · doi:10.1007/s00415-020-10324-5 · Cited by 6
Targeted Treatment Strategies for Mitochondria Dysfunction: Correlation with Neurological Disorders
Sharma, R., Malviya, R., Srivastava, S., Ahmad, I., Rab, S. O., & Uniyal, P. (2024) · Current Drug Targets · doi:10.2174/0113894501303824240604103732 · Cited by 5
Al‐Hakeim, H. K., Khudhair, H. N., Ranaei-Siadat, S.-O., Fatemi, F., Mirzajani, F., Niu, M., & Maes, M. H. J. (2025) · Scientific Reports · doi:10.1038/s41598-025-07735-7 · Cited by 5
Vastegani, Z. M., Ghaedi-Heidari, R., Oroujalian, A., Peymani, M., & Ghaedi, K. (2025) · Metabolic Brain Disease · doi:10.1007/s11011-025-01568-z · Cited by 4
Shiffer, D., Zamunér, A. R., Minonzio, M., Bulgheroni, M., Porta, A., Leone, R., Bottazzi, B., Garlanda, C., Colotta, F., Barbic, F., et al. (2023) · Frontiers in Physiology · doi:10.3389/fphys.2023.1168652 · Cited by 4
Association of inflammation and chronic fatigue syndrome in patients with Parkinson’s disease
Никитина, М. А., Bragina, E. Y., Ivanova, S. А., Boiko, A. S., Levchuk, L. A., Nazarenko, M. S., & Alifirova, V. M. (2024) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro202412409179 · Cited by 4
Clinical Aspects of Inflammation in Parkinson’s Disease
Thomas, M., & Adams, C. (2014) · Springer eBooks · doi:10.1007/978-3-319-08046-8_8 · Cited by 4
Unlocking the Secrets of Lrrk2 Function With Selective Kinase Inhibitors
Dzamko, N. L., & Halliday, G. M. (2013) · Future Neurology · doi:10.2217/fnl.13.9 · Cited by 4
Rimaud, D., Espeit, L., Mat, F. L., Cudel, C., Chaigneau, C., Lapole, T., & Millet, G. Y. (2023) · Research Square · doi:10.21203/rs.3.rs-2408446/v1 · Cited by 4
van der Heide, A., Kischkel, B., Bleeker‐Rovers, C. P., de Jonge, M. I., Bloem, B. R., Verbeek, M. M., Joosten, L. A. B., & Helmich, R. C. G. (2025) · npj Parkinson s Disease · doi:10.1038/s41531-025-01178-7 · Cited by 3
STING-dependent peripheral inflammaging drives neurodegeneration via extracellular vesicles
Öberg, M., Myers, C., Saffarzadeh, N., Marić, I., Murillo-Léon, M., Strömberg, A., Fabriková, D., Fabrik, I., Rivas-Galvez, L., Deshmukh, M. V., et al. (2026) · Cell Reports · doi:10.1016/j.celrep.2026.117640 · Cited by 3
Christiansen, J. R., Ferreira, S. A., Szymkowski, D. E., Jakobsson, J., Tansey, M. G., & Romero‐Ramos, M. (2025) · Neurobiology of Disease · doi:10.1016/j.nbd.2025.106803 · Cited by 3
VCAM-1 as an Endothelial Factor for Diagnosis of Dementia in Parkinson’s Disease
Sobhani, A., Ebrahimi, H., Ebrahimi, A., Saadatnia, M., Orooji, H., & Chitsaz, A. (2018) · Journal of Neurology and Neuroscience · doi:10.21767/2171-6625.1000243 · Cited by 3
Chen, X., Chen, S., Lai, X., Fu, J., Yang, J., Ou, R., Zhang, L., Wei, Q., Guo, X., & Shang, H. (2024) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2024.1459884 · Cited by 2
Jing, Y., Zhu, H., Yao, P., Chen, Y., Lai, X., He, Q., Yu, L., Lin, Y., & Kang, D. (2025) · Journal of Neurochemistry · doi:10.1111/jnc.70067 · Cited by 2
Yang, Y., Wang, J., Gao, L., Miao, J., Shen, F., & Liu, H. (2025) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2025.111652 · Cited by 2
No evidence for genetic role of the tumor necrosis factor pathway in Parkinson’s disease
Shahkhali, M. G., Liu, L., Somerville, E. N., Noyce, A. J., Gan‐Or, Z., & Senkevich, K. A. (2025) · npj Parkinson s Disease · doi:10.1038/s41531-025-01197-4 · Cited by 2
Alborghetti, M., Moliterni, C., Bianchini, E., Rinaldi, D., Caissutti, D., Capozzi, A., Radicati, F. G., Moschillo, A., Marino, M., Berardelli, I., et al. (2026) · Frontiers in Neuroscience · doi:10.3389/fnins.2026.1761550 · Cited by 2
Schreiner, G. E., dos Santos, L. S., Pereira, C. B., de Oliveira, C. P., Jacques, G. V., Sarmento, S. M. D. M., Brites, G. E., Fidélis, E. M., Gonçalves, I. L., Pinton, S., et al. (2026) · Brain Research · doi:10.1016/j.brainres.2026.150202 · Cited by 2
Proinflammatory Chemical Signaling: Cytokines
Nagamoto‐Combs, K., & Combs, C. K. (2014) · Springer eBooks · doi:10.1007/978-3-319-08046-8_6 · Cited by 2
Sulisthio, S., Jehosua, S. Y., & Momole, A. G. N. (2024) · Romanian Journal of Neurology · doi:10.37897/rjn.2024.2.18 · Cited by 2
Neuroprotective and Neurotrophic Effects of Astaxanthin on the Brain
Yook, J. S., & Soya, H. (2025) · Advances in neurobiology · doi:10.1007/978-981-95-0066-6_17 · Cited by 2
Neural Stem Cell-Based Therapeutic Approaches for Brain Repair
Saraiva, C., Santos, T., & Bernardino, L. I. (2018) · Springer eBooks · doi:10.1007/978-981-13-0944-1_21 · Cited by 2
Langley, M. R. (2017) · Iowa State University Digital Repository (Iowa State University) · Cited by 2
Serum cytokines are related to oxidative stress in Nigerian patients with Parkinson’s disease
Oderinu, K. A. (2019) · Journal of Medical Science And clinical Research · doi:10.18535/jmscr/v7i8.86 · Cited by 2
Metadata
- Authors
- Lindqvist, D., Kaufman, E., Brundin, L., Hall, S., Surova, Y., & Hansson, O.
- Affiliations
- Lund University (SE)
- Corresponding author
- Lindqvist, Daniel
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2012-10-17
- Volume
- 7
- Issue
- 10
- Pages
- e47387
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3474801
- OpenAlex
- W2107646604
- Cited by
- 236
- References
- 48
- Citations by year
- 2026: 14 · 2025: 19 · 2024: 22 · 2023: 19 · 2022: 27 · 2021: 21 · 2020: 17 · 2019: 16 · 2018: 16 · 2017: 13 · 2016: 15 · 2015: 15 · 2014: 16 · 2013: 6
- FWCI
- 7.74
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Lund University Publications (Lund University) (submittedVersion, other-oa)
- Funders
- Lunds Universitet
- Vetenskapsrådet
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
- Keywords
- Parkinson's disease, non-motor symptoms, fatigue, depression, anxiety, sleep disorders, inflammatory cytokines, interleukin-6, soluble interleukin-2 receptor, TNF-α, C-reactive protein, neuroinflammation
- MeSH terms
- C-Reactive Protein, Female, Humans, Male, Middle Aged, Motor Activity, Parkinson Disease, Regression Analysis, Tumor Necrosis Factor-alpha, Receptors, Interleukin-2, Interleukin-6, Confounding Factors, Epidemiologic, Case-Control Studies, Cytokines, Inflammation Mediators
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.